FDA’s Woodcock Prioritizes Trial Networks As Drug Development Solution
This article was originally published in The Tan Sheet
Culture change, not congressional action, is needed to change clinical trials system and move toward faster drug development, FDA’s drug center director tells the Energy & Commerce Committee.
You may also be interested in...
Called TransCelerate BioPharma, the initiative funded by 10 big drug firms will work to develop uniform clinical data standards and certification for trial sites and investigators, with deliverables expected by mid-2013.
FDA's Emergency Use Authorization for Malaria Drugs Could Hinder Trials of Other COVID-19 Treatments
Questions linger about the role the White House played in pushing the EUA, which comes with large product donations from Bayer and Sandoz that are expected to alleviate supply chain pressures for the drugs.
What's in – and what fell out of – the massive US stimulus package.